BeyondSpring (BYSI) Competitors $2.16 -0.04 (-1.82%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends BYSI vs. MGTA, MEIP, FULC, KMDA, BMEA, CMPS, ITOS, JSPR, RZLT, and PRQRShould you be buying BeyondSpring stock or one of its competitors? The main competitors of BeyondSpring include Magenta Therapeutics (MGTA), MEI Pharma (MEIP), Fulcrum Therapeutics (FULC), Kamada (KMDA), Biomea Fusion (BMEA), COMPASS Pathways (CMPS), iTeos Therapeutics (ITOS), Jasper Therapeutics (JSPR), Rezolute (RZLT), and ProQR Therapeutics (PRQR). These companies are all part of the "medical" sector. BeyondSpring vs. Magenta Therapeutics MEI Pharma Fulcrum Therapeutics Kamada Biomea Fusion COMPASS Pathways iTeos Therapeutics Jasper Therapeutics Rezolute ProQR Therapeutics Magenta Therapeutics (NASDAQ:MGTA) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations, media sentiment and community ranking. Does the MarketBeat Community favor MGTA or BYSI? BeyondSpring received 28 more outperform votes than Magenta Therapeutics when rated by MarketBeat users. Likewise, 66.79% of users gave BeyondSpring an outperform vote while only 57.09% of users gave Magenta Therapeutics an outperform vote. CompanyUnderperformOutperformMagenta TherapeuticsOutperform Votes15757.09% Underperform Votes11842.91% BeyondSpringOutperform Votes18566.79% Underperform Votes9233.21% Do institutionals & insiders hold more shares of MGTA or BYSI? 47.5% of Magenta Therapeutics shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 15.2% of Magenta Therapeutics shares are held by company insiders. Comparatively, 29.3% of BeyondSpring shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is MGTA or BYSI more profitable? BeyondSpring's return on equity of 0.00% beat Magenta Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Magenta TherapeuticsN/A -70.88% -57.27% BeyondSpring N/A N/A N/A Which has better valuation and earnings, MGTA or BYSI? BeyondSpring has higher revenue and earnings than Magenta Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMagenta TherapeuticsN/AN/A-$76.46MN/AN/ABeyondSpring$1.88M44.94-$21.03MN/AN/A Does the media favor MGTA or BYSI? In the previous week, Magenta Therapeutics' average media sentiment score of 0.95 beat BeyondSpring's score of 0.00 indicating that Magenta Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Magenta Therapeutics Positive BeyondSpring Neutral Which has more volatility and risk, MGTA or BYSI? Magenta Therapeutics has a beta of 2.12, suggesting that its share price is 112% more volatile than the S&P 500. Comparatively, BeyondSpring has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Do analysts rate MGTA or BYSI? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Magenta Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ABeyondSpring 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A SummaryBeyondSpring beats Magenta Therapeutics on 7 of the 10 factors compared between the two stocks. Ad Crypto 101 MediaMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…All you have to do is claim your free ticket to the event now… Get BeyondSpring News Delivered to You Automatically Sign up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BYSI vs. The Competition Export to ExcelMetricBeyondSpringPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$86.06M$7.42B$5.54B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E RatioN/A9.93114.8115.14Price / Sales44.94396.631,495.55100.10Price / CashN/A47.3939.6734.08Price / Book-2.375.324.665.02Net Income-$21.03M$153.56M$119.06M$225.46M7 Day Performance-4.42%0.13%0.80%0.37%1 Month Performance-15.95%15.23%5.65%3.57%1 Year Performance134.78%41.14%36.75%29.43% BeyondSpring Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BYSIBeyondSpringN/A$2.16-1.8%N/A+120.4%$86.06M$1.88M0.0080Positive NewsGap UpMGTAMagenta TherapeuticsN/A$0.70-7.7%N/A+0.0%$42.44MN/A0.0067Gap DownMEIPMEI Pharma4.7286 of 5 stars$3.07-1.0%$7.00+128.0%-56.3%$20.45M$65.30M1.15100Analyst ForecastNews CoverageGap DownFULCFulcrum Therapeutics3.4943 of 5 stars$3.21+1.6%$9.33+190.8%-14.4%$197.19M$81.63M-9.17100Upcoming EarningsShort Interest ↓Positive NewsKMDAKamada4.4454 of 5 stars$5.92+3.1%$14.50+144.9%+32.7%$340.28M$142.52M21.93360News CoverageGap UpHigh Trading VolumeBMEABiomea Fusion3.8084 of 5 stars$9.04-3.5%$30.50+237.4%-13.5%$327.61MN/A-2.2550Earnings ReportAnalyst ForecastAnalyst RevisionCMPSCOMPASS Pathways2.2856 of 5 stars$4.75-0.2%$30.67+545.6%-17.8%$324.85MN/A-2.06120Analyst ForecastShort Interest ↓News CoverageHigh Trading VolumeITOSiTeos Therapeutics3.0375 of 5 stars$8.81+4.3%$30.50+246.2%-11.1%$321.74M$12.60M-2.9490Upcoming EarningsJSPRJasper Therapeutics3.4255 of 5 stars$21.27+0.4%$74.86+251.9%+210.4%$321.18MN/A-4.1720RZLTRezolute3.7018 of 5 stars$5.50+0.4%$11.57+110.4%+436.6%$306.49MN/A-4.1440News CoveragePRQRProQR Therapeutics2.8802 of 5 stars$3.73+6.6%$5.88+57.5%+221.6%$304.67M$7.05M-12.86180Upcoming EarningsAnalyst Upgrade Related Companies and Tools Related Companies MGTA Competitors MEIP Competitors FULC Competitors KMDA Competitors BMEA Competitors CMPS Competitors ITOS Competitors JSPR Competitors RZLT Competitors PRQR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BYSI) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeyondSpring Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BeyondSpring With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
